Retatrutide vs AOD-9604

Side-by-side comparison of Retatrutide, AOD-9604 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Retatrutide Retatrutide (GIP/GLP-1/Glucagon Triple Agonist) Weight Loss AOD-9604 hGH Fragment 176-191 (Anti-Obesity Drug 9604) Weight Loss
Basics
Molecular type Triple GIP/GLP-1/Glucagon Receptor AgonisthGH C-terminal Fragment
Amino acids —16
Molecular weight —1,815.1 Da
Half-life ~6 days~30 min
Route(s) Subcutaneous injectionSubcutaneous, Oral (research)
Mechanism & Research
Primary mechanism Retatrutide activates three incretin and metabolic hormone receptors simultaneously. GLP-1 receptor agonism drives appetite suppression, slows gastric emptying, and reduces food intake — the primary mechanism shared with… AOD-9604 mimics the lipolytic (fat-breaking) action of the C-terminal fragment of growth hormone at the beta-3 adrenergic receptor in adipocytes. By activating beta-3 receptors, it promotes lipolysis (fat cell triglyceri…
Research status Phase 3 Trial Research Compound
Evidence summary Retatrutide is in Phase 3 clinical trials (NCT06052826) as of 2026, following highly positive Phase 2 data. The Phase 2 trial (NCT04881760, n=338) is the strongest weight loss signal from any pharmacological agent in hum… AOD-9604 completed Phase 2b trials for obesity (METRO study) before development was discontinued. Despite clear mechanistic rationale and positive preclinical data, the Phase 2b trial did not demonstrate statistically si…
Protocol & Dosing
Typical dose 2mg → 12mg weekly (titration)300–500 mcg/day
Frequency Once weeklyOnce daily
Duration Ongoing (Phase 3)8–12 weeks
Timing Same day each weekPre-workout or morning on empty stomach (for metabolic effects)
Safety
Common side effects
  • Nausea
  • Vomiting
  • Diarrhoea
  • Constipation
  • Injection site redness
  • Mild flushing
  • Headache (transient)
Contraindications
  • History of MEN2 or medullary thyroid carcinoma
  • Active pancreatitis
  • Pregnancy
  • Active cancer (theoretical, given GH receptor homology)
  • Pregnancy (no data)
Anti-doping Not Prohibited Prohibited (WADA S2)
Deeper reading
Related peptides Tirzepatide, Semaglutide, AOD-9604 Semaglutide, Ipamorelin, Tesamorelin
Full profile Read full Retatrutide profile → Read full AOD-9604 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.